The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial অনুযায়ী Judge, PK, Tuttle, KR, Staplin, N, Hauske, SJ, Zhu, D, Sardell, R, Cronin, L, Green, JB, Agrawal, N, Arimoto, R, Mayne, KJ, Sammons, E, Brueckmann, M, Shah, SV, Rossing, P, Nangaku, M, Landray, MJ, Wanner, C, Baigent, C, Haynes, R, Herrington, WG

অন্যান্য লেখক: “…EASi-KIDNEY Steering Committee…”